US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
CN100457118C
(zh)
|
2000-04-13 |
2009-02-04 |
法玛塞特有限公司 |
用于治疗肝炎病毒感染的3′-或2′-羟甲基取代的核苷衍生物
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
NZ547204A
(en)
|
2000-05-26 |
2008-01-31 |
Idenix Cayman Ltd |
Methods and compositions for treating flaviviruses and pestiviruses
|
IL155367A0
(en)
*
|
2000-10-23 |
2003-12-23 |
Smithkline Beecham Corp |
NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
MY134070A
(en)
|
2001-01-22 |
2007-11-30 |
Isis Pharmaceuticals Inc |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
JP2005504087A
(ja)
*
|
2001-09-28 |
2005-02-10 |
イデニクス(ケイマン)リミテツド |
4’が修飾されたヌクレオシドを使用するc型肝炎ウイルス治療のための方法および組成物
|
US7321033B2
(en)
*
|
2001-11-27 |
2008-01-22 |
Anadys Pharmaceuticals, Inc. |
3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
|
US7217815B2
(en)
*
|
2002-01-17 |
2007-05-15 |
Valeant Pharmaceuticals North America |
2-beta -modified-6-substituted adenosine analogs and their use as antiviral agents
|
AU2003225072A1
(en)
*
|
2002-04-19 |
2003-11-03 |
Smithkline Beecham Corporation |
Novel compounds
|
EP1551421A2
(en)
*
|
2002-06-21 |
2005-07-13 |
Merck & Co. Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
EP1572945A2
(en)
*
|
2002-06-27 |
2005-09-14 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
EP1536804A4
(en)
*
|
2002-06-28 |
2007-10-31 |
Idenix Cayman Ltd |
2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
NZ537662A
(en)
*
|
2002-06-28 |
2007-10-26 |
Idenix Cayman Ltd |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
EP2799442A1
(en)
*
|
2002-06-28 |
2014-11-05 |
IDENIX Pharmaceuticals, Inc. |
Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
|
EP1556399A4
(en)
*
|
2002-07-16 |
2007-09-26 |
Merck & Co Inc |
NUCLEOSIDE DERIVATIVES AS RNA-DEPENDENT VIRAL RNA POLYMERASE INHIBITORS
|
AU2003256619A1
(en)
*
|
2002-07-24 |
2004-02-09 |
Isis Pharmaceuticals, Inc. |
Pyrrolopyrimidine thionucleoside analogs as antivirals
|
BR0313164A
(pt)
|
2002-08-01 |
2007-07-17 |
Pharmasset Inc |
compostos com o sistema biciclo[4.2.1] nonano para o tratamento de infecções por flaviviridae
|
KR20050059199A
(ko)
*
|
2002-09-30 |
2005-06-17 |
제네랩스 테크놀로지스, 인코포레이티드 |
C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
|
HUE033832T2
(en)
*
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
|
GB0228545D0
(en)
*
|
2002-12-06 |
2003-01-15 |
Glaxo Group Ltd |
Novel compounds
|
MXPA05006230A
(es)
*
|
2002-12-12 |
2005-09-20 |
Idenix Cayman Ltd |
Proceso para la produccion de nucleosidos ramificados-2'.
|
RU2005123395A
(ru)
*
|
2002-12-23 |
2006-01-27 |
Айденикс (Кайман) Лимитед (Ky) |
Способ получения 3-нуклеозидных пролекарств
|
WO2004065398A2
(en)
*
|
2003-01-15 |
2004-08-05 |
Ribapharm Inc. |
Synthesis and use of 2'-substituted-n6-modified nucleosides
|
US7407962B2
(en)
|
2003-02-07 |
2008-08-05 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl compounds useful as inhibitors or protein kinases
|
US20070123531A1
(en)
*
|
2003-05-02 |
2007-05-31 |
Elan Pharmaceuticals, Inc. |
4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
|
JP4629037B2
(ja)
*
|
2003-05-02 |
2011-02-09 |
エラン ファーマシューティカルズ,インコーポレイテッド |
炎症疾患治療のためのブラジキニンb1受容体アンタゴニストとしての4−ブロモ−5−(2−クロロ−ベンゾイルアミノ)−1h−ピラゾール−3−カルボン酸(1−(アミノカルボニル)エト−1−イル)アミド誘導体および関連化合物
|
DE602004016992D1
(de)
*
|
2003-05-02 |
2008-11-20 |
Elan Pharm Inc |
4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3-carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
|
AU2004258750A1
(en)
*
|
2003-07-25 |
2005-02-03 |
Centre National De La Recherche Scientifique -Cnrs |
Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
|
CA2537450C
(en)
*
|
2003-09-05 |
2012-04-17 |
Anadys Pharmaceuticals, Inc. |
Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
|
US20050182252A1
(en)
*
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
KR20120091276A
(ko)
|
2004-02-20 |
2012-08-17 |
베링거 인겔하임 인터내셔날 게엠베하 |
바이러스 폴리머라제 억제제
|
ES2543834T3
(es)
|
2004-03-04 |
2015-08-24 |
K.U.Leuven Research & Development |
Fosfonato nucleósidos útiles como principios activos en composiciones farmacéuticas para el tratamiento de infecciones víricas y compuestos intermedios para su producción
|
WO2005123087A2
(en)
|
2004-06-15 |
2005-12-29 |
Merck & Co., Inc. |
C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
|
US20060040944A1
(en)
*
|
2004-06-23 |
2006-02-23 |
Gilles Gosselin |
5-Aza-7-deazapurine derivatives for treating Flaviviridae
|
US20070265222A1
(en)
*
|
2004-06-24 |
2007-11-15 |
Maccoss Malcolm |
Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
|
EP1804811A4
(en)
*
|
2004-09-24 |
2011-04-27 |
Idenix Cayman Ltd |
METHOD AND COMPOSITION FOR THE TREATMENT OF FLAVIVERS, PESTIVERS AND HEPACIVIRES
|
JP5089395B2
(ja)
|
2004-10-29 |
2012-12-05 |
バイオクライスト ファーマシューティカルズ, インコーポレイテッド |
治療用フロピリミジンおよびチエノピリミジン
|
TWI407956B
(zh)
*
|
2004-12-17 |
2013-09-11 |
Anadys Pharmaceuticals Inc |
3,5-二取代和3,5,7-三取代-3H-唑并及3H-噻唑并〔4,5-d〕嘧啶-2-酮化合物及其前藥
|
JP5002851B2
(ja)
*
|
2005-01-20 |
2012-08-15 |
独立行政法人理化学研究所 |
イミダゾピリジン誘導体
|
EP1898934A1
(en)
*
|
2005-03-09 |
2008-03-19 |
Idenix (Cayman) Limited |
Nucleosides with non-natural bases as anti-viral agents
|
AR053450A1
(es)
*
|
2005-03-25 |
2007-05-09 |
Glaxo Group Ltd |
Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38
|
JP2008535822A
(ja)
|
2005-03-25 |
2008-09-04 |
グラクソ グループ リミテッド |
新規化合物
|
EP1865959A2
(en)
*
|
2005-03-25 |
2007-12-19 |
Glaxo Group Limited |
Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
|
PE20100737A1
(es)
*
|
2005-03-25 |
2010-11-27 |
Glaxo Group Ltd |
Nuevos compuestos
|
US7514410B2
(en)
*
|
2005-03-29 |
2009-04-07 |
Biocryst Pharmaceuticals, Inc. |
Hepatitis C therapies
|
CA2606195C
(en)
*
|
2005-05-02 |
2015-03-31 |
Merck And Co., Inc. |
Hcv ns3 protease inhibitors
|
ES2415742T3
(es)
|
2005-05-13 |
2013-07-26 |
Vertex Pharmaceuticals (Canada) Incorporated |
Compuestos y procedimientos para el tratamiento o prevención de infecciones por flavivirus
|
TWI387603B
(zh)
*
|
2005-07-20 |
2013-03-01 |
Merck Sharp & Dohme |
Hcv ns3蛋白酶抑制劑
|
AU2006275605B2
(en)
*
|
2005-08-01 |
2011-01-06 |
Merck Sharp & Dohme Corp. |
Macrocyclic peptides as HCV NS3 protease inhibitors
|
JP2009513564A
(ja)
*
|
2005-08-09 |
2009-04-02 |
メルク エンド カムパニー インコーポレーテッド |
Rna依存性rnaウイルス感染の治療用のリボヌクレオシド環状アセタール誘導体
|
KR101538412B1
(ko)
|
2005-10-07 |
2015-07-22 |
엑셀리시스, 인코포레이티드 |
PI3Kα의 피리도피리미디논 억제제
|
CN102746298A
(zh)
|
2005-10-07 |
2012-10-24 |
埃克塞里艾克西斯公司 |
PI3Kα的吡啶并嘧啶酮抑制剂
|
EP1973920B1
(en)
|
2005-11-21 |
2010-07-21 |
Anadys Pharmaceuticals, Inc. |
Process for the preparation of 5-amino-3h-thiazolo [4,5-d] pyrimidin-2-one
|
CA2627319A1
(en)
*
|
2005-11-30 |
2007-06-07 |
Prakash Jagtap |
Purine derivatives and methods of use thereof
|
WO2007075876A2
(en)
*
|
2005-12-23 |
2007-07-05 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
MX2008012185A
(es)
*
|
2006-03-23 |
2008-10-02 |
Inotek Pharmaceuticals Corp |
Compuestos de purina y metodos de uso de los mismos.
|
GB0609492D0
(en)
*
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
ATE496924T1
(de)
*
|
2006-06-22 |
2011-02-15 |
Anadys Pharmaceuticals Inc |
Prodrugs von 5-amino-3-(3'-deoxy-beta-d- ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
DE602007012881D1
(en)
|
2006-07-18 |
2011-04-14 |
Anadys Pharmaceuticals Inc |
Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
|
WO2008032162A1
(en)
|
2006-09-15 |
2008-03-20 |
Pfizer Products Inc. |
Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
|
BRPI0717773A2
(pt)
*
|
2006-10-19 |
2013-11-05 |
Signal Pharm Llc |
Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase
|
CA2667165A1
(en)
*
|
2006-10-24 |
2008-05-02 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
AU2007309488B2
(en)
*
|
2006-10-24 |
2012-10-11 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
US8138164B2
(en)
*
|
2006-10-24 |
2012-03-20 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
WO2008057208A2
(en)
*
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
WO2008057209A1
(en)
*
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US8101595B2
(en)
*
|
2006-12-20 |
2012-01-24 |
Istituto di Ricerche di Biologia Molecolare P. Angletti SpA |
Antiviral indoles
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
AU2007342367B2
(en)
|
2007-01-05 |
2012-12-06 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
|
TW200838550A
(en)
*
|
2007-02-09 |
2008-10-01 |
Novartis Ag |
Organic compounds
|
GB0709791D0
(en)
*
|
2007-05-22 |
2007-06-27 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
US8183249B2
(en)
*
|
2007-07-12 |
2012-05-22 |
University Of South Florida |
Inhibitors of AKT/PKB with anti-tumor activity
|
AU2008277440A1
(en)
*
|
2007-07-17 |
2009-01-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Macrocyclic indole derivatives for the treatment of hepatitis C infections
|
JP5433573B2
(ja)
|
2007-07-19 |
2014-03-05 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ |
抗ウイルス剤としての大環状化合物
|
PT2268642E
(pt)
|
2008-04-23 |
2015-06-02 |
Gilead Sciences Inc |
Análogos de carba-nulceósidos 1¿-substituídos para tratamento antiviral
|
AU2009241445A1
(en)
|
2008-04-28 |
2009-11-05 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
KR20110065440A
(ko)
*
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
EP2313102A2
(en)
|
2008-07-03 |
2011-04-27 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
EP2310095B1
(en)
*
|
2008-07-22 |
2012-08-29 |
Merck Sharp & Dohme Corp. |
Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
GB0815968D0
(en)
*
|
2008-09-03 |
2008-10-08 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
AR073524A1
(es)
|
2008-09-30 |
2010-11-10 |
Exelixis Inc |
Piridopirimidinonas inhibidores de pi3k a y m tor
|
WO2010082050A1
(en)
|
2009-01-16 |
2010-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
AU2010221419B2
(en)
|
2009-03-02 |
2015-10-01 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
JP2012521359A
(ja)
*
|
2009-03-20 |
2012-09-13 |
アリオス バイオファーマ インク. |
置換されたヌクレオシドアナログおよびヌクレオチドアナログ
|
CA2756808A1
(en)
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted indolo-piperidine compounds
|
WO2010121576A2
(en)
*
|
2009-04-22 |
2010-10-28 |
Institute Of Organic Chemistry And Biochemistry Ascr,V.V.I. |
Novel 7-deazapurine nucleosides for therapeutic uses
|
PL2448938T3
(pl)
|
2009-06-29 |
2014-11-28 |
Incyte Holdings Corp |
Pirymidynony jako inhibitory PI3K
|
US8828930B2
(en)
|
2009-07-30 |
2014-09-09 |
Merck Sharp & Dohme Corp. |
Hepatitis C virus NS3 protease inhibitors
|
EP2459211A1
(en)
|
2009-07-31 |
2012-06-06 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon- to hepatitis c infected patients
|
CA2773773C
(en)
|
2009-09-21 |
2019-04-23 |
Gilead Sciences, Inc. |
Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
|
BR112012007122A2
(pt)
*
|
2009-09-29 |
2016-07-12 |
Janssen Products Lp |
derivados de fosforamidatos de nucleosídeos
|
ES2613664T3
(es)
|
2009-10-26 |
2017-05-25 |
Signal Pharmaceuticals, Llc |
Procedimientos de síntesis y purificación de compuestos de heteroarilo
|
WO2011075643A1
(en)
*
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
AR079529A1
(es)
*
|
2009-12-18 |
2012-02-01 |
Incyte Corp |
Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
|
ES2437933T3
(es)
*
|
2010-01-28 |
2014-01-15 |
F. Hoffmann-La Roche Ag |
4'-azido-nucleósidos como compuestos anti-VHC
|
TW201139436A
(en)
|
2010-02-09 |
2011-11-16 |
Exelixis Inc |
Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
|
MX2012011222A
(es)
|
2010-04-01 |
2013-01-18 |
Centre Nat Rech Scient |
Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
|
US9102938B2
(en)
|
2010-04-01 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
2′ and 5′ modified monomers and oligonucleotides
|
EP2558463A1
(en)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Fused derivatives as i3 inhibitors
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
JP5937073B2
(ja)
|
2010-07-19 |
2016-06-22 |
ギリード・サイエンシズ・インコーポレーテッド |
ジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法
|
AU2011280910B2
(en)
|
2010-07-22 |
2015-07-09 |
Gilead Sciences, Inc. |
Methods and compounds for treating Paramyxoviridae virus infections
|
GEP20156313B
(en)
|
2010-09-22 |
2015-07-10 |
Alios Biopharma Inc |
Substituted nucleotide analogs
|
US20120295911A1
(en)
|
2010-11-29 |
2012-11-22 |
Galleon Pharmaceuticals, Inc. |
Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
|
US9351972B2
(en)
|
2010-11-29 |
2016-05-31 |
Galleon Pharmaceuticals, Inc. |
Compounds as respiratory stimulants for treatment of breathing control disorders or diseases
|
TW201249844A
(en)
|
2010-12-20 |
2012-12-16 |
Incyte Corp |
N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
|
US9351989B2
(en)
|
2010-12-29 |
2016-05-31 |
Inhibitex, Inc. |
Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
US9126948B2
(en)
|
2011-03-25 |
2015-09-08 |
Incyte Holdings Corporation |
Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
SG10202010626PA
(en)
*
|
2011-03-31 |
2020-11-27 |
Schaefer Konstanze |
Perfluorinated compounds for the non-viral transfer of nucleic acids
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US9150603B2
(en)
|
2011-04-13 |
2015-10-06 |
Merck Sharp & Dohme Corp. |
2′-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
|
MX2013011944A
(es)
|
2011-04-13 |
2014-05-07 |
Merck Sharp & Dohme |
Derivados de nucleosidos 2'-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
|
WO2013009735A1
(en)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
WO2013009737A1
(en)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
|
US10112946B2
(en)
|
2011-07-22 |
2018-10-30 |
Glaxosmithkline Llc |
Composition
|
KR102131612B1
(ko)
|
2011-09-02 |
2020-07-08 |
인사이트 홀딩스 코포레이션 |
Pi3k 억제제로서 헤테로시클릴아민
|
BR112014009755B1
(pt)
|
2011-10-19 |
2022-09-13 |
Signal Pharmaceuticals, Llc |
Tratamento de câncer com inibidores de quinase tor
|
US9328138B2
(en)
|
2011-11-15 |
2016-05-03 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
CA3125862A1
(en)
|
2011-12-02 |
2013-06-06 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
EP2794630A4
(en)
|
2011-12-22 |
2015-04-01 |
Alios Biopharma Inc |
SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
|
BR112014020786A2
(pt)
|
2012-02-24 |
2020-10-27 |
Signal Pharmaceuticals, Llc |
método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência
|
CN104321333A
(zh)
|
2012-03-21 |
2015-01-28 |
沃泰克斯药物股份有限公司 |
硫代氨基磷酸酯核苷酸前药的固体形式
|
WO2013142157A1
(en)
|
2012-03-22 |
2013-09-26 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
WO2013179289A1
(en)
|
2012-05-31 |
2013-12-05 |
Bio-Lab Ltd. |
Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them
|
US9555036B2
(en)
|
2012-08-24 |
2017-01-31 |
Glaxosmithkline Llc |
Pyrazolopyrimidine compounds
|
US9556216B2
(en)
|
2012-08-31 |
2017-01-31 |
Novartis Ag |
2′-Ethynyl nucleoside derivatives for treatment of viral infections
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
RU2015119999A
(ru)
*
|
2012-10-29 |
2016-12-20 |
Кокристал Фарма, Инк. |
Пиримидиновые нуклеозиды и их монофосфатные пролекарства для лечения вырусных инфекций и рака
|
WO2014074883A1
(en)
*
|
2012-11-08 |
2014-05-15 |
Lyndor Biosciences L.L.C. |
Novel synthesis of ld101
|
WO2014081644A1
(en)
*
|
2012-11-20 |
2014-05-30 |
Glaxosmithkline Llc |
Novel compounds
|
PT2922549T
(pt)
*
|
2012-11-20 |
2017-09-01 |
Glaxosmithkline Llc |
Novos compostos
|
ES2625023T3
(es)
*
|
2012-11-20 |
2017-07-18 |
Glaxosmithkline Llc |
Compuestos novedosos
|
CN105188704B
(zh)
|
2013-01-16 |
2017-09-19 |
西格诺药品有限公司 |
被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
|
WO2014121417A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
CN105705511A
(zh)
|
2013-04-12 |
2016-06-22 |
艾其林医药公司 |
用于治疗hcv的氘化核苷前药
|
EP2986321A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
|
CA2909625C
(en)
|
2013-04-17 |
2021-06-01 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
|
PE20160041A1
(es)
|
2013-04-17 |
2016-01-28 |
Signal Pharm Llc |
FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA
|
JP6382946B2
(ja)
|
2013-04-17 |
2018-08-29 |
シグナル ファーマシューティカルズ,エルエルシー |
ジヒドロピラジノ−ピラジンによる癌治療
|
TWI631950B
(zh)
|
2013-04-17 |
2018-08-11 |
標誌製藥公司 |
藉二氫吡𠯤并吡𠯤治療癌症
|
TW201521725A
(zh)
|
2013-04-17 |
2015-06-16 |
Signal Pharm Llc |
使用tor激酶抑制劑組合療法以治療癌症之方法
|
CA2908957C
(en)
|
2013-04-17 |
2021-05-18 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
|
JP6401250B2
(ja)
|
2013-05-29 |
2018-10-10 |
シグナル ファーマシューティカルズ,エルエルシー |
7−(6−(2−ヒドロキシプロパン−2−イル)ピリジン−3−イル)−1−((trans)−4−メトキシシクロヘキシル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン、その固体形態の医薬組成物、及びその使用方法
|
WO2015038596A1
(en)
|
2013-09-11 |
2015-03-19 |
Emory University |
Nucleotide and nucleoside compositions and uses related thereto
|
US10449210B2
(en)
|
2014-02-13 |
2019-10-22 |
Ligand Pharmaceuticals Inc. |
Prodrug compounds and their uses
|
WO2015160880A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2015160868A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
US9718824B2
(en)
|
2014-04-16 |
2017-08-01 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
CN106687118A
(zh)
|
2014-07-02 |
2017-05-17 |
配体药物公司 |
前药化合物及其用途
|
EA201790189A1
(ru)
|
2014-07-14 |
2017-11-30 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
TWI698444B
(zh)
|
2014-10-29 |
2020-07-11 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
MA41607B1
(fr)
|
2015-02-27 |
2021-01-29 |
Incyte Corp |
Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
|
KR102363946B1
(ko)
|
2015-03-06 |
2022-02-17 |
아테아 파마슈티컬즈, 인크. |
HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
|
CN107820499B
(zh)
|
2015-04-28 |
2022-11-11 |
鲁汶大学研究与开发部 |
抗病毒化合物、其制备工艺、以及其用于治疗病毒感染的用途
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
PT3785717T
(pt)
|
2015-09-16 |
2022-04-14 |
Gilead Sciences Inc |
Métodos para o tratamento de infeções por coronaviridae
|
US10202412B2
(en)
|
2016-07-08 |
2019-02-12 |
Atea Pharmaceuticals, Inc. |
β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
|
KR20190043602A
(ko)
|
2016-09-07 |
2019-04-26 |
아테아 파마슈티컬즈, 인크. |
Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
|
EP3538099A4
(en)
|
2016-11-11 |
2020-06-17 |
The Queen's University of Belfast |
EFFICIENT AND EVOLUTIVE SYNTHESIS OF NICOTINOYLE RIBOSIDES AND NICOTINOYLE RIBOSIDES, THEIR MODIFIED DERIVATIVES, THEIR PHOSPHORYLATED ANALOGS, THEIR CONJUGATES WITH ADENYLYLE DINUCLEOTIDE AND NEW CRISTALLY FORMULATES
|
US11071747B2
(en)
|
2016-11-29 |
2021-07-27 |
University Of Iowa Research Foundation |
Use of NAD precursors for breast enhancement
|
JP7136795B2
(ja)
|
2016-11-29 |
2022-09-13 |
ユニバーシティー オブ アイオワ リサーチ ファウンデーション |
母体の健康および/または子の健康を向上させるためのnad前駆体の使用
|
GEP20237457B
(en)
|
2017-02-01 |
2023-01-10 |
Atea Pharmaceuticals Inc |
Nucleotide hemi-sulfate salt for treatment of hepatitis c virus
|
ES2961460T3
(es)
|
2017-03-14 |
2024-03-12 |
Gilead Sciences Inc |
Métodos para tratar las infecciones por coronavirus felinas
|
AR111490A1
(es)
|
2017-05-01 |
2019-07-17 |
Gilead Sciences Inc |
Formas cristalinas de propanoato de (s)-2-etilbutil 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)
|
SG11201912403SA
(en)
|
2017-06-22 |
2020-01-30 |
Celgene Corp |
Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
|
CN111093627B
(zh)
|
2017-07-11 |
2024-03-08 |
吉利德科学公司 |
用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
|
AU2019207625A1
(en)
|
2018-01-09 |
2020-07-30 |
Ligand Pharmaceuticals, Inc. |
Acetal compounds and therapeutic uses thereof
|
JP7060694B2
(ja)
*
|
2018-01-18 |
2022-04-26 |
アレイ バイオファーマ インコーポレイテッド |
Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物
|
CN108484705B
(zh)
*
|
2018-01-25 |
2020-09-01 |
中国医学科学院医药生物技术研究所 |
一种西奈芬净类似物及其制备方法
|
TW202012001A
(zh)
|
2018-04-10 |
2020-04-01 |
美商亞堤製藥公司 |
C型肝炎病毒(hcv)感染硬化之患者的治療
|
CN109776638A
(zh)
*
|
2019-04-01 |
2019-05-21 |
大连大学 |
一种5-Br-3’,5’-O-二乙酰基-2’-脱氧尿苷合成方法
|
CN109897081A
(zh)
*
|
2019-04-01 |
2019-06-18 |
大连大学 |
一种5-Br-2’,3’,5’-O-三乙酰基尿苷合成方法
|
CA3163424A1
(en)
|
2020-01-27 |
2021-08-05 |
Gilead Sciences, Inc. |
Methods for treating sars cov-2 infections
|
US10874687B1
(en)
|
2020-02-27 |
2020-12-29 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against COVID-19
|
AU2021234308C1
(en)
|
2020-03-12 |
2024-02-22 |
Gilead Sciences, Inc. |
Methods of preparing 1'-cyano nucleosides
|
CN115362004A
(zh)
|
2020-04-06 |
2022-11-18 |
吉利德科学公司 |
1’-氰基取代的碳核苷类似物的吸入制剂
|
CN111995649A
(zh)
*
|
2020-04-09 |
2020-11-27 |
瀚海新拓(杭州)生物医药有限公司 |
一种蝶啶酮核苷酸类似物及其药物组合物、制备方法和医药用途
|
JP2023528810A
(ja)
|
2020-05-29 |
2023-07-06 |
ギリアード サイエンシーズ, インコーポレイテッド |
レムデシビル治療方法
|
EP4172160A2
(en)
|
2020-06-24 |
2023-05-03 |
Gilead Sciences, Inc. |
1'-cyano nucleoside analogs and uses thereof
|
TW202233204A
(zh)
|
2020-08-27 |
2022-09-01 |
美商基利科學股份有限公司 |
用於治療病毒感染之化合物及方法
|
EP4196102A1
(en)
*
|
2020-10-02 |
2023-06-21 |
Sirnaomics, Inc. |
NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES
|
CN112851719A
(zh)
*
|
2021-03-10 |
2021-05-28 |
康化(上海)新药研发有限公司 |
一种贾斯帕霉素的合成方法
|
PE20240654A1
(es)
|
2021-08-20 |
2024-04-04 |
Shionogi & Co |
Derivados de nucleosido y profarmacos de los mismos que tienen accion inhibidora del crecimiento viral
|
WO2023102242A2
(en)
*
|
2021-12-03 |
2023-06-08 |
Quralis Corporation |
Splice switcher antisense oligonucleotides with modified backbone chemistries
|
TW202400185A
(zh)
|
2022-03-02 |
2024-01-01 |
美商基利科學股份有限公司 |
用於治療病毒感染的化合物及方法
|
CN117645636B
(zh)
*
|
2024-01-30 |
2024-04-16 |
深圳赛陆医疗科技有限公司 |
一种腺嘌呤叠氮中间体的制备方法
|